|
Table 1. Characteristics of approved innovative molecules. |
|||||
|
Molecule |
Lomitapide |
Mipomersen |
Permafibrate |
Inclisiran |
Bempedoic Acid |
|
Approval year |
2012 |
2013 |
2017 |
2020 |
2020 |
|
Indication |
Familial Hypercholes- terolemia |
Familial Hypercholes- terolemia |
Familial Hypercholes- terolemia and hyperlipidemia |
Familial Hypercholes- terolemia |
Familial Hypercholes- terolemia |
|
Route of administration |
Oral |
Subcutaneous |
Oral |
Subcutaneous |
Oral |
|
Dosage |
5mg/day |
200mg/week |
0.1mg/12hours |
300mg/6 months |
180mg/day |